Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ileana Rodicio

Allergy & Immunology Miami, FL Medical Doctor

NPI 1689638629 CMS profile 166724

9000 Sw 137Th Ave, Suite 213, Miami, FL 33186

Open in the dashboard

General payments

$24,355

761 records reported · program years 2019–2025

Research payments

$9,052

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,727,835 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ileana Rodicio of Miami, FL is reported in the CMS Open Payments database as having received $24,355 across 761 general payments and $9,052 in research payments paid to them. Separately, studies naming them as principal investigator received $3,727,835 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,618 159
2024 General $5,561 131
2023 General $3,429 125
2022 General $2,987 115
2021 General $2,256 83
2020 General $1,133 50
2020 Research $7,527 1
2019 General $2,372 98
2019 Research $1,525 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ileana Rodicio
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Ileana Rodicio were reported at $6,618. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Ileana Rodicio Allergy & Immunology median Middle half National median
2019 $2,372 $594 $163–$1,512 $163
2020 $1,133 $426 $106–$1,233 $114
2021 $2,256 $638 $157–$1,708 $132
2022 $2,987 $790 $205–$1,961 $149
2023 $3,429 $852 $220–$2,147 $160
2024 $5,561 $865 $203–$2,267 $164
2025 $6,618 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $5,866 80 payments
  2. AstraZeneca Pharmaceuticals LP $5,685 197 payments
  3. GlaxoSmithKline, LLC. $2,799 119 payments
  4. Regeneron Healthcare Solutions, Inc. $2,216 67 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $1,437 52 payments
  6. Amgen Inc. $1,071 50 payments
  7. Genentech USA, Inc. $810 30 payments
  8. OptiNose US, Inc. $705 19 payments
  9. Pharming Healthcare, Inc. $550 18 payments
  10. CSL Behring $435 16 payments
  11. Other $2,781 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,071 752 payments
  2. Consulting Fee $4,040 4 payments
  3. Education $161 4 payments
  4. Travel and Lodging $83 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $3,549 124 payments
  2. TEZSPIRE Respiratory $1,885 73 payments
  3. DUPIXENT Inflammation And Immunology $1,576 54 payments
  4. FASENRA $1,414 47 payments
  5. NUCALA $1,252 50 payments
  6. TRELEGY ELLIPTA $1,230 55 payments
  7. TEZSPIRE Inflammation $1,037 49 payments
  8. Xhance $705 19 payments
  9. AIRSUPRA $701 24 payments
  10. Xolair $660 29 payments
  11. Other $7,122 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $9,052 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,120

Median for Allergy/ Immunology: 449

Drug cost

$533,504

Median for Allergy/ Immunology: $169,700

Branded share of claims

25.4%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 42 $145,945
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 97 $72,197
Xolair Omalizumab Brand 24 $69,969
Fasenra Benralizumab Brand 11 $59,948
Tezspire Tezepelumab-Ekko Brand 13 $55,280
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 16 $38,038
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 52 $34,754
Breo Ellipta Fluticasone/Vilanterol Brand 27 $10,349
Azelastine Hcl Generic 229 $5,898
Fluocinolone Acetonide Generic 88 $5,396

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$40,971

Medicare's payments for the services billed

Medicare patients

71

Average age 70

Services billed

2,483

41 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 46%
Chronic kidney disease 31%
Diabetes 27%
Osteoporosis 27%
Depression 24%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $665
  • GENZYME CORPORATION $455
$1,120 42 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $466
  • Amgen Inc. $275
$741 13 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $376
$376 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $251
$251 11 —
TAKHZYRO
  • Takeda Pharmaceuticals U.S.A., Inc. $211
$211 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

763 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record